Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | NOS3 | P29474 | 1/20 | 0.46 |
| ▸ | NOS1 | P29475 | 1/20 | 0.46 |
| ▸ | NOS2 | P35228 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1399190 | 1.00 | MEN1 (0.52) | MEN1KMT2AL3MBTL1LMNAATM | |
| SCHEMBL14502401 | 0.89 | MEN1 (0.63) | MEN1KMT2AL3MBTL1LMNAATM | |
| SCHEMBL3884945 | 0.89 | MEN1 (0.63) | MEN1KMT2AL3MBTL1LMNAATM | |
| SCHEMBL3884943 | 0.89 | MEN1 (0.63) | MEN1KMT2AL3MBTL1LMNAATM | |
| SCHEMBL5752922 | 0.85 | CA12 (0.46) | MEN1KMT2ALMNAMAPTHPGD | |
| SCHEMBL5752920 | 0.85 | CA12 (0.46) | MEN1KMT2ALMNAMAPTHPGD | |
| SCHEMBL2081608 | 0.83 | MAPT (0.53) | MEN1KMT2AL3MBTL1LMNAMAPT | |
| SCHEMBL2081607 | 0.83 | MAPT (0.53) | MEN1KMT2AL3MBTL1LMNAMAPT | |
| SCHEMBL1205797 | 0.82 | MAPT (0.61) | MEN1KMT2ALMNAATMMAPT | |
| SCHEMBL1399137 | 0.82 | RAB9A (0.50) | MEN1KMT2AL3MBTL1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8022064-B2 | Phenylpentadienoyl derivatives and their use as PAR 1 antagonists | PIERRE FABRE MEDICAMENT (FR) | 2011-09-20 | — | — | US | disclosed |
| EP-2046748-B1 | PHENYLPENTADIENOYL DERIVATIVES AND THEIR USE AS PAR 1 ANTAGONISTS | PF MEDICAMENT (FR) | 2011-03-02 | — | — | EP | disclosed |
| US-20100003260-A1 | PHENYLPENTADIENOYL DERIVATIVES AND THEIR USE AS PAR 1 ANTAGONISTS | PIERRE FABRE MEDICAMENT (FR) | 2010-01-07 | — | — | US | disclosed |
| EP-2046748-A1 | PHENYLPENTADIENOYL DERIVATIVES AND THEIR USE AS PAR 1 ANTAGONISTS | Pierre Fabre Medicament (FR) | 2009-04-15 | — | — | EP | disclosed |
| WO-2007147822-A1 | PHENYLPENTADIENOYL DERIVATIVES AND THEIR USE AS PAR 1 ANTAGONISTS | PIERRE FABRE MEDICAMENT (FR) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003260-A1 | PHENYLPENTADIENOYL DERIVATIVES AND THEIR USE AS PAR 1 ANTAGONISTS | F2R, F2RL1, FPR1 | MEN1 1715/4885KMT2A 4020/4885L3MBTL1 2246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.